TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets criteria for persistent or worsening presentations of sinusitis~* Baseline score ≥9 on the Pediatric Rhinosinusitis Symptom Scale~Exclusion Criteria:~* Severe presentation (≥3 days of colored nasal discharge and fever ≥39°C~* Asthma/allergic rhinitis explains symptoms~* Allergy to amoxicillin-clavulanate~* Immotile cilia syndrome~* Cystic fibrosis~* Immunodeficiency~* Parental inability to read/write English or Spanish~* Other concurrent infection (e.g., pneumonia, acute otitis media, streptococcal pharyngitis)~* Systemic toxicity~* Wheezing on exam~* Antibiotic use within 15 days

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: ACTIVE_COMPARATOR): Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
- Treatment B (Type: PLACEBO_COMPARATOR): Placebo made to match the study antibiotic will be taken bid orally for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Past prior screening mammography (SM) interpreted as negative or benign (This screening must have been performed at Mayo Clinic Rochester, Minnesota).~2. Past prior SM interpreted as heterogeneously dense or extremely dense (This screening must have been performed at Mayo Clinic Rochester, Minnesota).~3. Women younger than 50 years who had not undergone prior mammography, as most of these women have dense breasts.~4. Subjects had to have at least one of the following risk factors:~   1. Known mutation in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2)~  2. History of chest, mediastinal, or axillary irradiation~  3. Personal history of breast cancer~  4. History of prior biopsy showing atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or atypical papilloma~  5. Gail or Claus model lifetime risk greater than or equal to 20%~  6. Gail model 5 year risk greater or equal to 2.5%~  7. Gail model 5 year risk greater or equal to 1.6%~  8. One first-degree relative with history of breast cancer~  9. Two second-degree relatives with history of breast cancer~Exclusion Criteria:~1. They are unable to understand and sign the consent form~2. They are pregnant or lactating~3. They are physically unable to sit upright and still for 40 minutes.~4. They have self-reported signs or symptoms of breast cancer (palpable mass, bloody nipple discharge, axillary mass etc.).~5. They have had needle biopsy within 3 months, or breast surgery within 1 year prior to the study.~6. They are currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor for adjuvant therapy or chemoprevention.

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mammography and Molecular Breast Imaging (Type: EXPERIMENTAL): Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has a diagnosis of RA according to the revised 1987 ACR classification criteria (Arnett et al 1987) for at least 6 months prior to randomization.~2. Patient has active disease as defined by the presence of 6 or more swollen joints (of 66 assessed) and 6 or more tender joints (of 68 assessed), and serum CRP ≥1.5 mg/dL or an ESR ≥28 mm/hour.~Exclusion Criteria:~1. Patient is unresponsive or intolerable to more than 2 biologic agents.~2. Patient has allergies or hypersensitivity to murine, chimeric, human, or humanized proteins.~3. Patient has current or past history of chronic infection with hepatitis B, hepatitis C, or infection with human immunodeficiency virus (HIV)-1 or -2 or who has a positive result to the screening test for these infections.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MabThera (Type: ACTIVE_COMPARATOR): rituximab
- CT-P10 (Type: ACTIVE_COMPARATOR): rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. diagnosis of essential hypertension~2. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy~3. provision of written informed consent~Exclusion criteria:~1. clinical conditions which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine for the planned duration of this trial (e.g. populations where labeling of either product recommends against its utilization)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan80mg+Amlodipine5mg (Type: EXPERIMENTAL): combination therapy
- amlodipine 5 mg (Type: ACTIVE_COMPARATOR): Monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 - 85 years~* Male and Female patients (females of child bearing potential must be using adequate contraceptive precautions)~* CHF (symptoms and/or sign of CHF, ejection fraction \< 40% (HfrEF) 14 or symptoms and/or signs of CHF, ejection fraction 40-49 % and NT-pro BNP \> 125 pg/ml, and at least one structural abnormality of left atrium or ventricle (HFmEF) 14 in stable conditions.~* Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit.~* Informed consent has to be given in written form.~Exclusion Criteria:~* Any other form of diabetes mellitus than type 2 diabetes mellitus~* Use of insulin or any SGLT-2 inhibitor within the past 10 weeks prior to the screening visit (visit 1).~* Patients with more than two blood glucose lowering medications~* Uncontrolled diabetes (fasting plasma glucose ≥ 240 mg/dl, HbA1c ≥ 10%)~* Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 6 months prior to study inclusion~* Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² (following the inclusion criteria of EMPA-REG OUTCOME study 1-3)~* Chronic heart failure NYHA stage IV~* Use of loop diuretics above furosemide \> 80 mg/day, or torasemide \>40 mg/day, or piretanide \> 6 mg/day~* Implanted pacemakers or defibrillators~* Any other relevant clinical contraindication of MRI examination~* Uncontrolled arterial hypertension (i.e. ≥ 180/110 mmHg)~* Severe disorders of the gastrointestinal tract or other diseases which interfere with the pharmacodynamics and pharmacokinetics of study drugs~* Significant laboratory abnormalities such as Serum Glutamate-Oxaloacetate-Transaminase (SGOT) or Serum Glutamate-Pyruvate-Transaminase (SGPT) levels more than 3 x above the upper limit of normal range

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
- Empagliflozin (Type: ACTIVE_COMPARATOR): Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meets diagnostic criteria for isolated cervical dystonia~* Has moderate severity with a baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) - Total score of at least 20 and a TWSTRS-Severity subscale score or at least 15~* Has been using stable doses of focal dystonia medications for at least 3 months and willing to continue through end of study~Exclusion Criteria:~* Cervical dystonia attributable to an underlying etiology, such as traumatic torticollis or tardive torticollis; predominant retrocollis or anterocollis cervical dystonia~* Significant dystonia in other body areas, or is currently being treated with botulinum toxin for dystonia in other areas than isolated cervical dystonia~* Neurological abnormalities other than cervical dystonia~* History of severe dysphagia or aspiration, or current clinically significant swallowing disorder~* Previous neck surgery, phenol injection to the neck muscles, myotomy or denervation surgery in the neck/shoulder region, or intrathecal baclofen~* Marked limitation on passive range of motion that suggests contractures or other structural abnormality, e.g. cervical contractures or cervical spinal deformity~* Profound atrophy of cervical musculature~* Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis~* Suboptimal efficacy response to any prior botulinum toxin type A product, when a previous treatment produced more optimal therapeutic response, as judged subjectively by the Investigator~* Previous treatment with any botulinum toxin product for any condition within the 6 months prior to Screening and during the study; presence of any blood coagulation disorder; or on anticoagulation treatment with international normalized ratio (INR) \> 3.5

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- daxibotulinumtoxinA (DAXI) for injection (Type: EXPERIMENTAL): DAXI for injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals 14 years of age and older~* English proficiency sufficient for study participation~* Diagnosis of Axis I unipolar major depression, per screening Mini International Neuro-Psychiatric Interview (MINI)~* Depressive symptoms of mild to moderate intensity, per score of 14-28 on screening Beck Depression Inventory-II (BDI)~* Able to attend all required study sessions~Exclusion Criteria:~* Cognitive Impairment, as per Folstein Mini-mental Status Exam Score \< 24~* Use of any antidepressant medication or herbal/nutraceutical mood therapy within the 2 months prior to screening, or during study period~* Use of psychotherapy during study period~* Use of any yoga or other mind-body practices during study period, other than study intervention~* Per screening MINI, diagnosis of any Axis I disorder other than unipolar major depression, such as bipolar disorder, dysthymia or anxiety disorders~* Per screening MINI, diagnosis of substance use disorders within prior 3 months~* Per screening MINI, current suicidal ideation or past suicide attempts~* Severe depressive symptoms, as per screening BDI score \> 28

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hatha Yoga Practice Group (Type: EXPERIMENTAL): Participants in this group practiced 90-minute sessions of hatha yoga exercises twice weekly for a total of 8 weeks.
- Attention Control Education Group (Type: ACTIVE_COMPARATOR): Participants in this group attended 90-minute educational seminars on yoga history twice weekly for a total of 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Postmenopausal, ambulatory women between 50 and 70 years old who are generally in good health.~* Must have low bone mineral density and meet specific eligibility criteria.~Key Exclusion Criteria:~-Subjects must not currently be receiving any medication that affects bone metabolism or have an underlying condition that affects their ability to take alendronate or receive denosumab.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 3 (Type: PLACEBO_COMPARATOR): Placebo for denosumab and placebo for alendronate
- 1 (Type: EXPERIMENTAL): denosumab and placebo for alendronate
- 2 (Type: ACTIVE_COMPARATOR): Placebo for denosumab and alendronate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A proven, either probable or possible invasive fungal infection which is refractory to standard antifungal therapies.~* Subjects who received \>72 hours of systemic empiric antibacterial therapy and are neutropenic (\<500 neutrophils per mm3 and, have had fever that has reached an oral temperature \>38c (or \>100.4f)twice in the last 48 hours, or~have a recurrence of fever (oral temperature, \>38c or \>100.4F) while receiving broad spectrum antibacterial therapy after prior resolution of fever while on antibacterial therapy.~* Able to take oral medication or take medication via enteral feeding tube.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Male or female WITH haemoglobinopathy, Myelodysplastic Syndromes or other inherited or acquired anaemia (e.g. MPD, Diamond-blackfan anaemia and other rare anaemias) patients ≥ 18 years and weighing \>40kg.~* Lifetime minimum of \> 20 units of packed red blood cell transfusions~* Normal or minimally abnormal cardiac function~Exclusion criteria:~* Contraindication to MRI scans~* High risk myelodysplastic syndromes patients and patients with other haematological and non-haematological malignancies who are not expected to benefit from chelation therapy due to the rapid progression of their disease~* Patients with uncontrolled high blood pressure~* An organ transplant less than 3 months previously~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with at least 2 documented episodes of paroxysmal Atrial Fibrillation (AF) which are not responders to at least one antiarrythmic drug~Exclusion Criteria:~* Previous left atrial ablation procedure or surgery~* left atrium diameter \> 50mm~* presence of intracardiac thrombus~* Left ventricular ejection fraction \< 40%~* Heart failure class III-IV~* Severe valvulopathies~* Acute coronary syndrome or cardiac surgery within the previous 3 months of enrollment~* Transient ischemic attack/stroke within the previous 6 months of enrollment~* life expectancy less than 1 year~* Any contraindication to the procedure according to the current clinical practice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: ACTIVE_COMPARATOR): Conventional protocol for cryoablation:~At least 2 applications of 180s each
- Study Arm (Type: EXPERIMENTAL): Experimental protocol for cryoablation:~Time to effect + 1 minute and a bonus application of 120s

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DHEA Against Vaginal Atrophy - Safety Study of 12 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Postmenopausal women (non-hysterectomized)~* Women between 40 and 75 years of age.~* Willing to participate in the study and sign an informed consent.~* Women who have self-identified symptom(s) of vaginal atrophy.~* Willing to have endometrial biopsy at screening and end of study (Week 52).~Main Exclusion Criteria:~* Undiagnosed abnormal genital bleeding.~* Hypertension equal to or above 140/90 mm Hg.~* The administration of any investigational drug within 30 days of screening visit.~* Endometrial hyperplasia, cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DHEA (Type: EXPERIMENTAL): 0.5% DHEA (intravaginal)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risperidone and Suicidality in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 19-60 years of age~2. Diagnosis of major depressive disorder, currently severe with suicidality~3. A total score of Montgomery-Asberg Depression Rating Scale (MADRS) =/\> 25 with the suicide sub-score =/\> 4~4. Currently is taking an antidepressant at a therapeutic dose for longer than 3 weeks~5. In good physical health~Exclusion Criteria:~1. Depression without suicidality~2. Presence of major psychiatric conditions other than major depressive disorder, such as bipolar disorder, schizophrenia, or anxiety disorders (except for generalized anxiety disorder)~3. Depressive symptoms induced by alcohol or substance abuse~4. Psychotic features which are predominant at the initial evaluation~5. Unstable major medical illness, such as cardiac disease or diabetes~6. Female subjects who are pregnant, breastfeeding, or, if of child-bearing potential, unwilling to use adequate birth control measures

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- risperidone (Type: EXPERIMENTAL): risperidone
- placebo (Type: PLACEBO_COMPARATOR): placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete